首页> 外文期刊>Journal of Pharmacy and Pharmacology >Astragaloside IV inhibited the activity of CYP1A2 in liver microsomes and influenced theophylline pharmacokinetics in rats
【24h】

Astragaloside IV inhibited the activity of CYP1A2 in liver microsomes and influenced theophylline pharmacokinetics in rats

机译:黄芪甲苷抑制大鼠肝微粒体中CYP1A2的活性并影响茶碱的药代动力学

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives With the growing popularity of herbal and natural medicinal products, attention has turned to possible interactions between these products and pharmaceutical drugs. In this study, we examined whether astragaloside IV (AGS-IV) could inhibit the activity of CYP1A2 in rat liver microsomes in vitro and in vivo. Methods The effect of AGS-IV on CYP1A2 activity was investigated using probe substrates: phenacetin in vitro and theophylline in vivo. Phenacetin was incubated in rat liver microsomes with or without AGS-IV, and the mechanism, kinetics and type of inhibition were determined. The inhibitory effect of AGS-IV on CYP1A2 activity in rats was also determined using theophylline in vivo. The pharmacokinetics of theophylline were observed after a single or week-long treatment with AGS-IV. Key findings AGS-IV was found to be a competitive inhibitor with a Ki value of 6.29 μm in vitro. In the multiple-pretreatment rat group, it was found to have a significantly higher area under the concentration-time curve (AUC) for theophylline, as well as a lower apparent oral total body clearance value (CL/F). In contrast, no significant difference in metabolism of theophylline was found for the single pretreatment group. Conclusions These findings suggest that AGS-IV is a potent inhibitor of CYP1A2. This work offers a useful reference for the reasonable and safe use of clinically prescribed herbal or natural products to avoid unnecessary herb-drug interactions.
机译:目标随着草药和天然药物产品的日益普及,人们已将注意力转向这些产品与药物之间的可能相互作用。在这项研究中,我们检查了黄芪甲苷IV(AGS-IV)是否可以在体外和体内抑制大鼠肝脏微粒体内CYP1A2的活性。方法使用探针基质:体外非那西汀和体内茶碱,研究AGS-IV对CYP1A2活性的影响。将非那西丁在有或没有AGS-IV的大鼠肝微粒体中孵育,并确定其抑制机理,动力学和抑制类型。还使用体内茶碱测定了AGS-IV对大鼠CYP1A2活性的抑制作用。用AGS-IV单次或长达一周的治疗后观察到茶碱的药代动力学。主要发现AGS-IV是一种竞争性抑制剂,在体外的Ki值为6.29μm。在多次预处理大鼠组中,发现茶碱的浓度-时间曲线(AUC)下的面积显着较高,而口服表观全身清除率值(CL / F)较低。相反,单个预处理组的茶碱代谢没有显着差异。结论这些发现表明,AGS-IV是CYP1A2的有效抑制剂。这项工作为合理安全地使用临床处方的草药或天然产品提供了有用的参考,以避免不必要的草药-药物相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号